Shengqing Gu, Ph.D.
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
About Dr. Shengqing Gu
Shengqing (Stan) Gu graduated from University of Toronto with a PhD in Medical Biophysics and did postdoctoral training at Harvard Medical School and Dana-Farber Cancer Institute. He joined University of Texas MD Anderson Cancer Center as Assistant Professor in November 2022. He is strongly committed to the professional fulfillment and career advancement of his trainees.
Read More
Present Title & Affiliation
Primary Appointment
Faculty, Division of Cancer Medicine, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Assistant Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Assistant Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Our lab is interested in enhancing the efficacy of cancer immunotherapy by modulating cell-cell interactions. To achieve this goal, we integrate various cutting-edge experimental and computational approaches in the areas of functional genomics, single-cell/spatial multi-omics, data mining, machine learning, and mathematical modeling, among others. Here are several research directions in the lab:
Context-dependent gene regulation
We aim to perturb gene expression in the tumor to enhance immunotherapy with desired immunomodulatory effects. Our previous research revealed that gene expression regulation depends on the cellular genetic/epigenetic context. For example, cancer cells with different baseline NF-κB expression can show different responses to SMAC mimetics in upregulating MHC-I. Therefore, to achieve the desired immunomodulatory effects, we need rational, personalized strategies to perturb gene expression. To this end, we will integrate functional genomics, single-cell/spatial technologies, and machine learning approaches to elucidate the context-dependent gene regulation mechanisms.
Novel mechanisms of cell-cell interaction
The essence of the anti-cancer immune response lies in cell-cell interactions. Our previous research investigated multiple aspects of such interaction at different levels. We applied machine learning models to public bulk tumor gene expression data and identified SERPINB9 and MAN2A1 as regulators of cancer cells’ response to cytotoxic T cells. Using in vivo CRISPR screens, we identified a ubiquitin E3 ligase, COP1, whose inhibition can alter macrophage infiltration and sensitize tumors to immunotherapy. We also identified multiple regulators of the MHC-I/II antigen presentation machinery in cancer cells that can modulate cancer-T-cell interaction. We are interested in other cell-cell interaction mechanisms in the tumor microenvironment.
Dynamics of anti-cancer immune response
With the expanding options for cancer therapy and vast possibilities for drug scheduling, we need quantitative models of the response dynamics to rationally design combination strategies. Our previous research integrated a branching model and ODE models to simulate the dynamics of ovarian cancer clinical course and predict optimal combinations of surgery and chemotherapy for this disease. We also used clonal tracing of cancer cells to characterize the dynamics and heterogeneity of response to immune checkpoint blockade therapy. We aim to further integrate experimental/clinical data and mathematical modeling to quantify the dynamics of the anti-cancer immune response, which can help us gain mechanistic insights into this biological process and optimize combination therapy strategies.
Education & Training
Degree-Granting Education
| 2016 | University of Toronto, Ontario, CA, Medical Biophysics, Ph.D |
| 2007 | Peking University, Beijing, CN, Biological Sciences, BS |
Postgraduate Training
| 2016-2021 | Postdoctoral Fellow, Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, 2021 - 2022
Postdoctoral Fellow, Department of Data Science, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, Boston, MA, 2016 - 2021
Other Professional Positions
Graduate Researcher, University of Toronto, University Health Network Department of Medical Biophysics, Ontario, 2008 - 2016
Technician, Chinese Academy of Sciences - Institute of Genetics and Developmental Biology, Beijing, 2007 - 2008
Honors & Awards
| 2022 - Present | Underrepresented Early Career Scientists Travel Award, Dana-Farber Cancer Institute |
| 2021 - 2022 | SITC Annual Meeting Young Investigator Travel Award, Society for Immunotherapy of Cancer |
| 2021 | AACR-Doreen J. Putrah Cancer Research Foundation Scholar-in-Training Award, American Association for Cancer Research |
| 2015 | AACR-Marsha Rivkin Center for Ovarian Cancer Research Scholar-in-Training Award, American Association for Cancer Research |
| 2014 - 2015 | Department of Medical Biophysics Doctoral Completion Award, University of Toronto |
| 2011 | ORT Travel Award, University Health Network |
| 2011 | Canadian Cancer Research Conference Travel Award, Canadian Cancer Research |
| 2010 - 2011 | Department of Medical Biophysics Travel Award, University of Toronto |
| 2009 - 2010 | University of Toronto Award Fund, University of Toronto |
| 2004 - 2006 | Peking University Principal’s Undergraduate Research Award, Peking University |
| 2004 | Beijing 21st Undergraduate Physics Contest 3rd Prize, Peking University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Tackling cancer immune evasion - antigen presentation and beyond. Invited. Houston, Texas, US.
- 2025. Integrative approaches to tackle cancer immune escape. Invited. Houston, Texas, US.
- 2024. Integrative Approaches to enhance cancer immune response. Invited. Houston, Texas, US.
- 2024. Integrative Approaches to Enhance Cancer Immune Response. Invited. Allison Institute Symposium. Houston, Texas, US.
- 2023. Integrative Approaches to Enhance Cancer Immune Response. Invited. Houston, Texas, US.
- 2023. Integrative Approaches to Enhance Cancer Immune Response. Invited. Houston, Texas, US.
- 2023. Integrative Approaches to Enhance Cancer Immune Response. Invited. Houston, Texas, US.
- 2023. Integrative Approaches to Enhance Cancer Immune Response. Invited. Houston, Texas, US.
Regional Presentations
- 2024. Modulating Cancer Antigen Presentation to Potentiate Immunotherapy. Invited. GCC Single Cell Omics Symposium, US.
National Presentations
- 2023. Hippo signaling pathway regulates cancer-cell-intrinsic MHC-II expression in melanoma. Conference. Hippo signaling pathway regulates cancer-cell-intrinsic MHC-II expression in melanoma. Orlando, FL, US.
- 2022. Integrative approaches to modulate antigen presentation and boost cancer immune response. Conference. Integrative approaches to modulate antigen presentation and boost cancer immune response. New Orleans, LA, US.
- 2021. Increasing MHC-I expression to potentiate immune checkpoint blockade therapy. Conference. Increasing MHC-I expression to potentiate immune checkpoint blockade therapy. Washington, DC, US.
- 2021. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Conference. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade, US.
- 2019. Clonal tracing reveals distinct sources of resistance to immune checkpoint blockade. Conference. Clonal tracing reveals distinct sources of resistance to immune checkpoint blockade. Atlanta, GA, US.
- 2017. Identification of resistance to immune checkpoint blockade. Conference. Identification of resistance to immune checkpoint blockade. Boston, MA, US.
- 2015. Computational modeling of serous ovarian carcinoma dynamics: implications for screening and therapy. Conference. Computational modeling of serous ovarian carcinoma dynamics: implications for screening and therapy. Orlando, FL, US.
- 2015. Computational modeling of serous ovarian carcinoma dynamics: implications for screening and therapy. Conference. Computational modeling of serous ovarian carcinoma dynamics: implications for screening and therapy. San Francisco, CA, US.
- 2015. Computational modeling of serous ovarian carcinoma dynamics: implications for screening and therapy. Conference. Computational modeling of serous ovarian carcinoma dynamics: implications for screening and therapy. Philadelphia, PA, US.
- 2012. Shp2 Is Required for Chronic Myeloid Leukemia Initiation and Maintenance. Conference. Shp2 Is Required for Chronic Myeloid Leukemia Initiation and Maintenance. Chicago, IL, US.
- 2011. Requirement for Shp2 in Chronic Myeloid Leukemia Initiation and Maintenance. Conference. Requirement for Shp2 in Chronic Myeloid Leukemia Initiation and Maintenance. Saxtons River, VT, US.
International Presentations
- 2024. Increasing MHC-I expression to potentiate cancer immunotherapy. Invited. Princess Margaret Cancer Center - MD Anderson Cancer Center Joint Symposium. Toronto, CA.
- 2021. In vivo CRISPR screens identify E3 ligase Cop1 as a cancer immunotherapy target by modulating macrophage infiltration. Conference. In vivo CRISPR screens identify E3 ligase Cop1 as a cancer immunotherapy target by modulating macrophage infiltration. Virtual, US.
- 2018. Microenvironmental factors shape resistance patterns to immune checkpoint blockade. Conference. Microenvironmental factors shape resistance patterns to immune checkpoint blockade. New York, US.
- 2015. Computational modeling of high-grade serous ovarian carcinoma dynamics: implications for screening and therapy. Conference. Computational modeling of high-grade serous ovarian carcinoma dynamics: implications for screening and therapy. Suzhou, CN.
- 2014. Computational modeling of high-grade serous ovarian cancer. Invited. 5th Annual Ovarian Cancer Symposium. Toronto, CA.
- 2011. Shp2 Is Required for Chronic Myeloid Leukemia Initiation and Maintenance. Conference. Shp2 Is Required for Chronic Myeloid Leukemia Initiation and Maintenance. Toronto, CA.
Formal Peers
- 2023. Integrative approaches to enhance cancer immune response. Invited. Houston, TX, US.
- 2023. Integrative approaches to enhance cancer immune response. Invited. Houston, TX, US.
- 2021. Integrative approaches to enhance cancer immune response. Invited. Virtual, US.
- 2019. Deconvolution of the resistance to immunotherapy. Invited. Virtual, US.
- 2018. Deconvoluting the resistance to immune checkpoint blockade. Invited, US.
Grant & Contract Support
| Date: | 2023 - 2026 |
| Title: | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1K22CA279077-01 |
| Date: | 2023 - 2024 |
| Title: | Novel approach to sensitize acute myeloid leukemia (AML) to immunotherapy |
| Funding Source: | PhRMA Foundation |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Immunomodulatory effects of nuclear receptors in triple-negative breast cancer |
| Funding Source: | Medical Foundation Sara Elizabeth O’Brien Trust Postdoctoral Fellowship |
| Role: | PI |
| Title: | The regulatory mechanisms of MHC-I-dependent antigen presentation |
| Funding Source: | Kinship Foundation |
| Role: | PI |
| Title: | Novel CAR-T therapy for acute myeloid leukemia |
| Funding Source: | Concern Foundation |
| Role: | PI |
| Title: | Modulating MHC-I expression to sensitize ovarian cancer to immunotherapy |
| Funding Source: | Andrew Sabin |
| Role: | PI |
| Title: | Modulating MHC-I expression to sensitize ovarian cancer to immunotherapy |
| Funding Source: | Ovarian Cancer Research Alliance |
| Role: | PI |
| Title: | Novel CAR-T therapy for ovarian cancer |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| Title: | Principal Investigator, Evolution of antigen presentation defects in cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Novel CAR-T therapy for ovarian cancer |
| Funding Source: | Ovarian Cancer SPORE at MDACC |
| Role: | PI |
| Title: | Evolution of antigen presentation defects in cancer |
| Funding Source: | Rita Allen Foundation |
| Role: | PI |
| Title: | Modulating cancer-T-cell interaction to sensitize ovarian cancer to immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Principal Investigator, Novel CAR-T therapy for ovarian cancer |
| Funding Source: | Institution Research Grant |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Nie H, Liao L, Zielinski RJ, Gomez JA, Basi AV, Seeley EH, Tan L, Bilecz AJ, Zhou W, Liu H, Wang C, Wu S, Qi Y, Miyamoto T, Severi F, Goldman AR, Gu S, Sood AK, Jazaeri AA, Drapkin R, Claiborne DT, Zhang N, Lorenzi PL, Burks JK, Lengyel E, Gottlieb E, Zhang R. Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res 85(18):3471-3489, 2025. e-Pub 2025. PMID: 40658600.
- Chen W, Baker T, Zhang Z, Ogilvie HA, Van Loo P, Gu SS. Evolutionary trajectories of immune escape across cancers. bioRxiv, 2025. e-Pub 2025. PMID: 39868264.
- Li, D, Geng, K, Hao, Y, Gu, J, Kumar, S, Olson, AT, Kuismi, CC, Kim, HM, Pan, Y, Sherman, F, Williams, AM, Li, Y, Li, F, Chen, T, Thakurdin, C, Ranieri, M, Meynardie, M, Levin, DS, Stephens, J, Chafitz, A, Chen, J, Donald-Paladino, MS, Powell, JM, Zhang, ZY, Chen, W, Ploszaj, M, Han, H, Gu, S, Zhang, T, Hu, B, Nacev, B, Kaiza, ME, Berger, AH, Wang, X, Li, J, Sun, X, Liu, Y, Zhang, X, Bruno, TC, Gray, NS, Nabet, B, Wong, KK, Zhang, H. Targeted degradation of oncogenic KRASG12Vtriggers antitumor immunity in lung cancer models. Journal of Clinical Investigation 135(2), 2025. e-Pub 2025. PMID: 39718828.
- Mason M, Ó L, Halkola AS, Wang W, Mall R, Xiao X, Kaufman J, Fu J, Pfeil J, Banerjee J, Chung V, Chang H, Chasalow SD, Lin HY, Chai R, Yu T, Finotello F, Mirtti T, Mäyränpää MI, Bao J, Verschuren EW, Ahmed EI, Ceccarelli M, Miller LD, Monaco G, Hendrickx WRL, Sherif S, Yang L, Tang M, Gu SS, Zhang W, Zhang Y, Zeng Z, Das Sahu A, Liu Y, Yang W, Bedognetti D, Tang J, Eduati F, Laajala TD, Geese WJ, Guinney J, Szustakowski JD, Vincent BG, Carbone DP. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J Transl Med 22(1):190, 2024. e-Pub 2024. PMID: 38383458.
- Zhang Y, Xiang G, Jiang AY, Lynch A, Zeng Z, Wang C, Zhang W, Fan J, Kang J, Gu SS, Wan C, Zhang B, Liu XS, Brown M, Meyer CA. MetaTiME integrates single-cell gene expression to characterize the meta-components of the tumor immune microenvironment. Nat Commun 14(1):2634, 2023. e-Pub 2023. PMID: 37149682.
- Sahu A, Wang X, Munson P, Klomp JPG, Wang X, Gu SS, Han Y, Qian G, Nicol P, Zeng Z, Wang C, Tokheim C, Zhang W, Fu J, Wang J, Nair NU, Rens JAP, Bourajjaj M, Jansen B, Leenders I, Lemmers J, Musters M, van Zanten S, van Zelst L, Worthington J, Liu JS, Juric D, Meyer CA, Oubrie A, Liu XS, Fisher DE, Flaherty KT. Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha. Cancer Discov 13(3):672-701, 2023. e-Pub 2023. PMID: 36745048.
- Soto-Feliciano YM, Sánchez-Rivera FJ, Perner F, Barrows DW, Kastenhuber ER, Ho YJ, Carroll T, Xiong Y, Anand D, Soshnev AA, Gates L, Beytagh MC, Cheon D, Gu S, Liu XS, Krivtsov AV, Meneses M, de Stanchina E, Stone RM, Armstrong SA, Lowe SW, Allis CD. A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition. Cancer Discov 13(1):146-169, 2023. e-Pub 2023. PMID: 36264143.
- Zeng Z, Gu SS, Ouardaoui N, Tymm C, Yang L, Wong CJ, Li D, Zhang W, Wang X, Weirather JL, Rodig SJ, Hodi FS, Brown M, Liu XS. Hippo signaling pathway regulates cancer cell-intrinsic MHC-II expression. Cancer Immunol Res 10(12):1559-1569, 2022. e-Pub 2022. PMID: 36219700.
- Zeng Z, Gu SS, Wong CJ, Yang L, Ouardaoui N, Li D, Zhang W, Brown M, Liu XS. Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response. Sci Adv 8(41):eabm8564, 2022. e-Pub 2022. PMID: 36240281.
- Zhang W, Roy Burman SS, Chen J, Donovan KA, Cao Y, Shu C, Zhang B, Zeng Z, Gu S, Zhang Y, Li D, Fischer ES, Tokheim C, Shirley Liu X. Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation. Genomics Proteomics Bioinformatics 20(5):882-898, 2022. e-Pub 2022. PMID: 36494034.
- Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, Gu S, Tang Q, Zhang Y, Syamala S, Seo JH, Bell C, O'Connor E, Liu Y, Schaeffer EM, Jeffrey Karnes R, Weinmann S, Davicioni E, Morrissey C, Cejas P, Ellis L, Loda M, Wucherpfennig KW, Pomerantz MM, Spratt DE, Corey E, Freedman ML, Shirley Liu X, Brown M, Long HW, Labbé DP. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun 13(1):2559, 2022. e-Pub 2022. PMID: 35562350.
- Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall ACP, Henrich JA, Zhu Q, Nowak RP, Kim YJ, Parvin S, Cremer A, Olsen SN, Eleuteri NA, Pikman Y, McGeehan GM, Stegmaier K, Letai A, Fischer ES, Liu XS, Armstrong SA. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer 3(5):595-613, 2022. e-Pub 2022. PMID: 35534777.
- Zhou J, Wu Z, Zhang Z, Goss L, McFarland J, Nagaraja A, Xie Y, Gu S, Peng K, Zeng Y, Zhang X, Long H, Nakagawa H, Rustgi A, Diehl JA, Meyerson M, Wong KK, Bass A. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut 71(4):665-675, 2022. e-Pub 2022. PMID: 33789967.
- Zeng Z, Wong CJ, Yang L, Ouardaoui N, Li D, Zhang W, Gu S, Zhang Y, Liu Y, Wang X, Fu J, Zhou L, Zhang B, Kim S, Yates KB, Brown M, Freeman GJ, Uppaluri R, Manguso R, Liu XS. TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Res 50(D1):D1391-D1397, 2022. e-Pub 2022. PMID: 34534350.
- Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35058328.
- Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, Traugh N, Zeng Z, Zhang Y, Li Z, Zhang B, Fu J, Xiao T, Li W, Meyer CA, Chu J, Jiang P, Cejas P, Lim K, Long H, Brown M, Liu XS. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell 184(21):5357-5374.e22, 2021. e-Pub 2021. PMID: 34582788.
- Qiu X, Feit AS, Feiglin A, Xie Y, Kesten N, Taing L, Perkins J, Gu S, Li Y, Cejas P, Zhou N, Jeselsohn R, Brown M, Shirley Liu X, Long HW. CoBRA: Containerized Bioinformatics Workflow for Reproducible ChIP/ATAC-seq Analysis. Genomics Proteomics Bioinformatics 19(4):652-661, 2021. e-Pub 2021. PMID: 34284136.
- Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, Tu D, Parulekar WR, Nankivell M, Kehoe S, Chi DS, Levine DA, Bernardini MQ, Rosen B, Oza A, Brown M, Neel BG. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A 118(25), 2021. e-Pub 2021. PMID: 34161278.
- Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X, Manos MP, Font-Tello A, Gjini E, Lako A, Lim K, Conway J, Tewari AK, Zeng Z, Sahu AD, Tokheim C, Weirather JL, Fu J, Zhang Y, Kroger B, Liang JH, Cejas P, Freeman GJ, Rodig S, Long HW, Gewurz BE, Hodi FS, Brown M, Liu XS. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov 11(6):1524-1541, 2021. e-Pub 2021. PMID: 33589424.
- Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, Foster CJR, Loomis CA, Olvera N, Dao F, Levine DA, Weinberg RA, Neel BG. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discov 11(2):362-383, 2021. e-Pub 2021. PMID: 33158842.
- Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res 81(1):158-173, 2021. e-Pub 2021. PMID: 33158814.
- Shi S, Gu S, Han T, Zhang W, Huang L, Li Z, Pan D, Fu J, Ge J, Brown M, Zhang P, Jiang P, Wucherpfennig KW, Liu XS. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. Clin Cancer Res 26(22):5990-6002, 2020. e-Pub 2020. PMID: 32723834.
- Gu SS, Wang X, Hu X, Jiang P, Li Z, Traugh N, Bu X, Tang Q, Wang C, Zeng Z, Fu J, Meyer C, Zhang Y, Cejas P, Lim K, Wang J, Zhang W, Tokheim C, Sahu AD, Xing X, Kroger B, Ouyang Z, Long H, Freeman GJ, Brown M, Liu XS. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol 21(1):263, 2020. e-Pub 2020. PMID: 33059736.
- Li Z, Wang B, Gu S, Jiang P, Sahu A, Chen CH, Han T, Shi S, Wang X, Traugh N, Liu H, Liu Y, Wu Q, Brown M, Xiao T, Boland GM, Shirley Liu X. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Genomics Proteomics Bioinformatics 18(1):26-40, 2020. e-Pub 2020. PMID: 32413516.
- Zhang J, Hu X, Wang J, Sahu AD, Cohen D, Song L, Ouyang Z, Fan J, Wang B, Fu J, Gu S, Sade-Feldman M, Hacohen N, Li W, Ying X, Li B, Liu XS. Immune receptor repertoires in pediatric and adult acute myeloid leukemia. Genome Med 11(1):73, 2019. e-Pub 2019. PMID: 31771646.
- Du W, He J, Zhou W, Shu S, Li J, Liu W, Deng Y, Lu C, Lin S, Ma Y, He Y, Zheng J, Zhu J, Bai L, Li X, Yao J, Hu D, Gu S, Li H, Guo A, Huang S, Feng X, Hu D. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia. J Transl Med 17(1):191, 2019. e-Pub 2019. PMID: 31171000.
- Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, Wang B, Gu S, Jiang P, Fan J, Ying X, Zhang J, Carroll MC, Wucherpfennig KW, Hacohen N, Zhang F, Zhang P, Liu JS, Li B, Liu XS. Publisher Correction: Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet 51(6):1068, 2019. e-Pub 2019. PMID: 31101897.
- Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, Wang B, Gu S, Jiang P, Fan J, Ying X, Zhang J, Carroll MC, Wucherpfennig KW, Hacohen N, Zhang F, Zhang P, Liu JS, Li B, Liu XS. Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet 51(3):560-567, 2019. e-Pub 2019. PMID: 30742113.
- Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550-1558, 2018. e-Pub 2018. PMID: 30127393.
- Gu S, Sayad A, Chan G, Yang W, Lu Z, Virtanen C, Van Etten RA, Neel BG. SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia 32(1):203-213, 2018. e-Pub 2018. PMID: 28804122.
- Gu S, Chan WW, Mohi G, Rosenbaum J, Sayad A, Lu Z, Virtanen C, Li S, Neel BG, Van Etten RA. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127(14):1803-13, 2016. e-Pub 2016. PMID: 26773044.
- Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, Gonen M, Levine RL, Nimer SD. Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. J Exp Med 213(1):25-34, 2016. e-Pub 2016. PMID: 26666262.
- Chan G, Gu S, Neel BG. Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis. Blood 121(18):3594-8, 2013. e-Pub 2013. PMID: 23444405.
- Wu X, Yin J, Simpson J, Kim KH, Gu S, Hong JH, Bayliss P, Backx PH, Neel BG, Araki T. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol 32(19):3872-90, 2012. e-Pub 2012. PMID: 22826437.
- Levaot N, Voytyuk O, Dimitriou I, Sircoulomb F, Chandrakumar A, Deckert M, Krzyzanowski PM, Scotter A, Gu S, Janmohamed S, Cong F, Simoncic PD, Ueki Y, La Rose J, Rottapel R. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 147(6):1324-39, 2011. e-Pub 2011. PMID: 22153076.
- Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood 117(16):4253-61, 2011. e-Pub 2011. PMID: 21398220.
Patient Reviews
CV information above last modified March 30, 2026